President Trump signs a sweeping new proclamation to bring pharmaceutical manufacturing back to the United States—targeting one of America’s most critical national security vulnerabilities. Despite leading the world in drug innovation, the U.S. relies heavily on foreign supply chains for key ingredients and finished medicines. This episode breaks down the risks, the policy response—including tariffs and onshoring incentives—and why the future of medicine may depend on rebuilding America’s industrial base.